Abstract
Purpose: :
To determine the incidence of intraocular pressure (IOP) increase in patients receiving ranibizumab.
Methods: :
This is a retrospective chart review of 210 patients receiving 716 intravitreal injections of ranibizumab from July 2006 - July 2007.
Results: :
IOP rose > 21 mmHg in 1.2% (n=9) of patients, and > 30 mmHg in 0.5% (n=1). Patients received an average of 3.4 injections over 7.6 months. Maximum IOP was 39 mmHg after 9 injections. In IOP responders, 44% had a history of glaucoma or ocular hypertension. There was no significant difference between preinjection (14 mmHg) and final postinjection IOP (14.3 mmHg) (p=0.44).
Conclusions: :
There is a low incidence of IOP rise after ranibizumab. Patients with glaucoma or ocular hypertension may be at increased risk.
Keywords: intraocular pressure • injection • age-related macular degeneration